Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
2016 Jan;54(5):73953
For instance, a number of ongoing or completed trials are evaluating inhibitors of the PI3K-AKT-mTOR cascade, such as gedatolisib (NCT03065062) in advanced solid tumors, capivasertib (NCT04305496) in hormone receptor-positive breast cancer, and alpelisib (NCT02437318), which has shown efficacy in advanced breast cancer and is already approved for PIK3CA-mutated cases
doi: 10.3390/nu12092573 12
no combo data CagriSema (Cag + Sema) NDA under FDA review Retatrutide Alone Phase 3 ongoing Feature Estimated grey-market cost Cagrilintide + Retatrutide $600-$1,200/month CagriSema (Cag + Sema) $500-$900/month Retatrutide Alone $300-$600/month Cost ranges reflect typical research-grade pricing across COA-verified suppliers as of June 2026 - verify supplier pricing before ordering
The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study
US$ 29.84
US$ 27.59
US$ 20.07
US$ 26.24
